-
Posted by
Two Blokes Wed at 9:45 PM -
Filed in
Stock
-
1 view
Ongoing tariff disputes and President Trump's drug pricing order heighten uncertainties for AbbVie Inc. and Pfizer Inc. The more uncertain the time, the more investors should focus on return vectors that are less ambiguous. ABBV's superior dividend track record, safer payout ratio, consistent share buybacks, and robust margins make it an overall better package compared to PFE.
